K-V Pharmaceutical Company Announces $200 Million Private Debt Offering

K-V Pharmaceutical Company (NYSE: KVa/KVb) (the "Company") announced today that it intends to offer $200 million of senior secured notes due 2015 (the "Notes") in a private placement, subject to market conditions. The Notes will be offered only to accredited investors pursuant to Regulation D under the Securities Act of 1933, as amended (the "Securities Act"). The Notes have not been registered under the Securities Act or any state or other securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements of the Securities Act and applicable state securities laws. The Company intends to use the net proceeds from the offering of the Notes to repay in full the Company's outstanding obligations under its credit agreement with U.S. Healthcare I, L.L.C. and U.S. Healthcare II, L.L.C. (including the payment of related premiums) and terminate the related future loan commitments, to establish an escrow reserve for one year of interest payments on the Notes and for general corporate purposes. This press release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any securities.